Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 4929-4932, November 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerr, I. G.
Right arrow Articles by Poplack, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerr, I. G.
Right arrow Articles by Poplack, D. G.

Effect of Intravenous Dose and Schedule on Cerebrospinal Fluid Pharmacokinetics of 5-Fluorouracil in the Monkey

Ian G. Kerr1, Solomon Zimm, Jerry M. Collins2, Dondra O'Neill and David G. Poplack

Clinical Pharmacology [I. G. K., J. M. C.] and Pediatric [S. Z., D. O., D. G. P.] Branches, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20205

There is little information regarding the pharmacology of 5-fluorouracil (5-FUra) in the central nervous system (CNS), despite its role in the treatment of diseases with CNS metastases and recent reports of neurotoxicity. In this study, the plasma and cerebrospinal fluid (CSF) pharmacokinetics of 5-FUra were examined in a primate model. Following a bolus dose, the area under the concentration versus time curves for 5-FUra in CSF was 48% of the plasma area under the concentration versus time curves. For continuous infusion of 5-FUra, the area under the concentration versus time curves ratio for CSF:plasma was 20 or 11%, depending upon the infusion rate. The mechanism for variations in CSF exposure based upon the pattern of plasma delivery is consistent with local metabolism of 5-FUra in the CNS. These findings should be considered in the evaluation of delivery schedules which are intended to maximize drug delivery to the CNS and/or minimize neurotoxicity.

1 Recipient of a Gordon E. Richards Fellowship from the Canadian Cancer Society. Present address: Ontario Cancer Foundation, Toronto-Bayview Clinic, 2075 Bayview Ave., Toronto, Ontario M4N 3M5 Canada.

2 To whom requests for reprints should be addressed, at Bldg. 10, Room 6N119, NIH, Bethesda, MD 20205.

Received 5/21/84. Accepted 8/10/84.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. C.S. Au-Yeung, K. W. Riggs, N. Gruber, and D. W. Rurak
The Use of Microdialysis for the Study of Drug Kinetics: Central Nervous System Pharmacokinetics of Diphenhydramine in Fetal, Newborn, and Adult Sheep
Drug Metab. Dispos., August 1, 2007; 35(8): 1285 - 1291.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.